Today Cellect Biotechnology Ltd. (NASDAQ:APOP) with $1.93 share price, reached 1-year low with $1.79 PT or 7.00 % below. It was reported on Feb, 5 according to Barchart.com. The company has $12.58 million MC. $880,530 less could be NASDAQ:APOP valuation at $1.79 share price.
Ticker’s shares touched $1.9291 during the last trading session after 10.69% change.Cellect Biotechnology Ltd. has 175,884 shares volume, 1022.78% up from normal. APOP is downtrending and has moved 57.50% since February 5, 2018. APOP underperformed by 57.50% the S&P500.
Cellect Biotechnology Ltd. (NASDAQ:APOP)’s earnings report is expected on March, 18., as reported by RTT. earnings per share of $-0.36 is 125.00 % down from 2018’s $-0.16 EPS. Analysts at Wall Street see Cellect Biotechnology Ltd.’s 24.14 % negative EPS growth compared to $-0.29 earnings per share for previous quarter.
For more Cellect Biotechnology Ltd. (NASDAQ:APOP) news published briefly go to: Prnewswire.com, Prnewswire.com, Prnewswire.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “Cellect Receives Multiple Patent Grants – PR Newswire” published on November 05, 2018, “Positive Results of Orthopedic Treatment With the Use of ApoGraftâ„¢ Enriched Stem Cells Derived From Fat Tissues – PR Newswire” on October 18, 2018, “Cellect Appoints Dr. Ronit Bakimer-Kleiner as Chief Development Officer – PR Newswire” with a publish date: October 19, 2017, “Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors – GlobeNewswire” and the last “Arsanis and CohBar among Healthcare gainers; G1 Therapeutics and ReShape Lifesciences among the losers – Seeking Alpha” with publication date: November 27, 2018.
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The company has $12.58 million market cap. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Currently it has negative earnings.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.